sequential therapy and drug resistance in cll in the era of targeted agents
Published 5 years ago • 70 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
1:01
cll resistance mechanisms in the era of novel agents
-
5:40
recommendations for biomarker analysis in cll: updates from eric 2024
-
6:54
biomarker-guided treatment of cll in the chemo-free era
-
1:29
the importance of treatment sequencing in cll
-
2:23
the importance of genomic testing in cll in the era of novel therapies
-
37:57
automated summarization of clinical notes
-
21:24
cell surface markers: cd3, cd4, cd8, cd19, cd28, cd16, cd56
-
2:18:01
27. overview of clinical stations
-
3:51
the role of frontline chemoimmunotherapy in the era of novel agents in cll
-
1:16
the efficacy of car t-cell therapy in richter's transformation
-
1:42
the future of cll treatment: aiming for long-lasting remission
-
1:20
mechanisms of resistance to targeted therapies in cll
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
1:43
exploring the role of non-coding rnas in cll biology
-
1:25
prognostic and predictive biomarkers in cll and their potential in guiding treatment decisions
-
1:35
the value of ctcs and cfdna as novel biomarkers in multiple myeloma
-
1:43
the importance of understanding cellular functionality to develop biological therapies for cll
-
1:00
the future of cll treatment: chemotherapy and targeted inhibitors
-
2:59
the tests that are needed to make a definitive diagnosis of cll
-
0:56
the current treatment landscape in cll
-
2:34
sequencing of therapies in patients with r/r cll